MedTrace Logo

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

NCT03631043 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-19

No results posted yet for this study

Summary

This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.

Conditions

  • Smoldering Plasma Cell Myeloma

Interventions

PROCEDURE

Biopsy Specimen Radiography

Undergo collection of blood and bone marrow

DRUG

Lenalidomide

Given PO

BIOLOGICAL

Vaccine Therapy

Given personalized vaccine SC

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Krina Patel · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-21
Primary Completion
2025-12-10
Completion
2025-12-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03631043 on ClinicalTrials.gov